StockNews.com Begins Coverage on Oragenics (NYSE:OGEN)

Equities research analysts at StockNews.com started coverage on shares of Oragenics (NYSE:OGEN) in a research report issued on Wednesday. The firm set a “sell” rating on the stock.

Oragenics Trading Up 0.7 %

OGEN stock opened at $0.29 on Wednesday. The stock has a 50-day moving average price of $0.30 and a 200-day moving average price of $0.39. Oragenics has a 1-year low of $0.25 and a 1-year high of $3.43. The firm has a market cap of $3.51 million, a PE ratio of -0.04 and a beta of 0.85.

About Oragenics

Oragenics, Inc, a development-stage company, engages in the research and development of antibiotics for infectious diseases in the United States. The company engages in the development and commercialization of NT-CoV2-1, an intranasal vaccine candidate that provides immunity from the novel severe acute respiratory syndrome coronavirus.